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Introduction
Mucins are heavily glycosylated glycoproteins that are major components of mucus covering the luminal surface epithelium of the respiratory, gastrointestinal, and reproductive tracts (Kim, Y.S., Gum, J., Jr., et al. 1996) . Twenty-one distinct epithelial mucin genes (MUC1-2, MUC3A, MUC3B, MUC4, MUC5AC, MUC5B, have been identified to date (Bobek, L.A., Tsai, H., et al. 1993 , Dufosse, J., Porchet, N., et al. 1993 , Gendler, S.J., Lancaster, C.A., et al. 1990 , Gum, J.R., Byrd, J.C., et al. 1989 , Gum, J.R., Jr., Hicks, J.W., et al. 2003 , Itoh, Y., Kamata-Sakurai, M., et al. 2008 , Lan, M.S., Batra, S.K., et al. 1990 , Lapensee, L., Paquette, Y., et al. 1997 , Ligtenberg, M.J., Vos, H.L., et al. 1990 , Meezaman, D., Charles, P., et al. 1994 , Morgan, S.M., Samulowitz, U., et al. 1999 , Porchet, N., Nguyen, V.C., et al. 1991 , Shankar, V., Pichan, P., et al. 1997 , Toribara, N.W., Roberton, A.M., et al. 1993 , Wreschner, D.H., Hareuveni, M., et al. 1990 , Yin, B.W. and Lloyd, K.O. 2001 ). In situ hybridization and immunohistochemical studies have shown that these mucins have distinct expression patterns with respect to organ, tissue and cell type (Audie, J.P., Janin, , De Bolos, C., Garrido, M., et al. 1995 , Ho, J.J., Siddiki, B., et al. 1995 , Machado, J.C., Nogueira, A.M., et al. 2000 , Nielsen, P.A., Mandel, U., et al. 1996 .
In human stomach as well as in other organs, altered mucin expression is seen in cancer and precancerous lesions, both at the protein (apomucin) and at the glycosylation levels (Carneiro, F., Amado, M., et al. 1994 , David, L., Nesland, J.M., et al. 1992 , Ho, J.J., Siddiki, B., et al. 1995 , Reis, C.A., David, L., et al. 1997 , Reis, C.A., David, L., et al. 1998 . The majority of gastric carcinomas, particularly of the intestinal type (Lauren, P. 1965) , which is the most common in populations at high risk, are preceded by a carcinogenesis pathway characterized by the following sequential steps: infection by Helicobacter pylori, superficial gastritis, atrophic gastritis, intestinal metaplasia (IM) and dysplasia (Correa, P. 1988 , Correa, P. 1992 (Audie, J.P., Janin, A., et al. 1993 , Carrato, C., Balague, C., et al. 1994 , Gambus, G., de Bolos, C., et al. 1993 , Ho, J.J., Siddiki, B., et al. 1995 , Ho, S.B., Niehans, G.A., et al. 1993 , Reis, C.A., David, L., et al. 1998 . Preneoplastic IM lesions of the stomach are characterized by the transdifferentiation of the gastric mucosa to an intestinal phenotype (Mesquita, P., Jonckheere, N., et al. 2003) . with alterations in the mucin expression pattern including de novo expression of MUC2, mostly in goblet cells (Reis, C.A., David, L., et al. 1999) . Thirty percent of gastric carcinomas, including all carcinomas of the mucinous type, also aberrantly express the intestinal mucin MUC2 (Pinto-de-Sousa, J., David, L., et al. 2002 , Reis, C.A., David, L., et al. 2000 .
At the glycosylation level, cancer and precancerous lesions also show dramatic alterationse.g. aberrant expression of sialylated carbohydrate structures -that often co-localize with altered expression of apomucin. The Sialyl-Tn antigen (Neu5Acα2-6GalNAc-O-Ser/Thr) is a simple mucin-type carbohydrate antigen rarely observed in normal tissues but highly expressed in most gastric (David, L., Nesland, J.M., et al. 1992) , colorectal (Itzkowitz, S.H., Bloom, E.J., et al. 1990 ), ovarian (Kobayashi, H., Terao, T., et al. 1992) , breast (Leivonen, M., Nordling, S., et al. 2001 , Yonezawa, S., Tachikawa, T., et al. 1992 , and pancreatic (Kim, G.E., Bae, H.I., et al. 2002) carcinomas. Sialyl-Tn is also aberrantly expressed in premalignant lesions of the gastrointestinal tract, such as IM of the stomach (David, L., Nesland, J.M., et al. 1992) , adenomatous polyps of the intestine (Itzkowitz, S.H., Bloom, E.J., et al. 1992) , and chronic ulcerative colitis (Karlen, P., Young, E., et al. 1998 ). It has also been shown to be an independent indicator of poor prognosis in carcinomas and in sera from patients with gastric (Nakagoe, T., Sawai, T., et al. 2002 , Werther, J.L., Rivera-MacMurray, S., et al. 1994 , Werther, J.L., Tatematsu, M., et al. 1996 , colorectal (Itzkowitz, S.H., Bloom, E.J., et al. 1990) , and ovarian cancer (Kobayashi, H., Terao, T., et al. 1992) .
Observations suggest that MUC2 and Sialyl-Tn are aberrantly expressed in IM and colocalize in goblet cells (Ferreira, B., Marcos, N.T., et al. 2006 ). This suggests, but does not prove, that MUC2 is the carrier protein of the newly synthesized Sialyl-Tn antigen in IM and possibly also in gastric carcinomas. Previous studies have shown that MUC2 and Sialyl-Tn are co-expressed in colorectal cancer cells (Sternberg, L.R., Byrd, J.C., et al. 1999 , Wang, F., Goto, M., et al. 2001 ) but no information is available for gastric cancer. Methods currently used to identify the mucin carrying a cancer-associated carbohydrate structure are cumbersome, so only few studies go beyond co-localization studies in cancer tissues (Baeckstrom, D., Hansson, G.C., et al. 1991 , Baeckstrom, D., Nilsson, O., et al. 1993 , Baeckstrom, D., Zhang, K., et al. 1995 , Fernandez-Rodriguez, J., Dwir, O., et al. 2001 , Hanski, C., Hanski, M.L., et al. 1995 , Ho, J.J., Siddiki, B., et al. 1995 , Robbe-Masselot, C., Herrmann, A., et al. 2008 ).
Proximity ligation assays (PLA) are a versatile tool for identification of biomolecule complexes and post-translational modifications in serum samples, tissue sections and cultured cells. The method offers a new and potentially revolutionary opportunity for glycopeptide identification, provided that antibodies for both protein and carbohydrate are available. PLA is based on the use of a pair of proximity probes against two partners in a protein complex.
These proximity probes are made by conjugation of oligonucleotides to affinity reagents, e.g.
antibodies. Only upon binding of a pair of proximity probes to a protein or protein complex will a ligation dependent product be formed. This can either be a linear DNA molecule for amplification by PCR (Fredriksson, S., Gullberg, M., et al. 2002) 
MATERIALS AND METHODS

Human Tissue Samples
Gastric specimens were obtained from surgical gastrectomies performed at Hospital S. João, Medical Faculty (Porto, Portugal). Tissue fragments were fixed in 10% formaldehyde and embedded in paraffin wax. Serial sections were cut and used for immunohistochemistry and PLA. We evaluated 12 cases with gastric carcinoma that were classified as intestinal (n=7), diffuse (n=4), and mixed (n=1) (Lauren, P. 1965) . IM was observed in 8 cases of gastric mucosa adjacent to the carcinoma cases ( Table 1 ). The use of retrospective samples where informed consent cannot be obtained is authorized for research studies by the Portuguese Law.
Monoclonal antibodies, Immunohistochemistry
Serial sections from formalin-fixed paraffin-embedded gastric specimens were used for immunostaining and PLA. The avidin-biotin-peroxidase complex (ABC) method was applied.
The paraffin sections were dewaxed and then treated with 0.3% hydrogen peroxide (H 2 O 2 ) in methanol for 30 min, to block endogenous peroxidase. Sections to be stained for MUC2 were pretreated with neuraminidase for exposure of the epitope detected by antibody PMH1 (Reis, C.A., Sorensen, T., et al. 1998 ). The sections were incubated for 20 min with normal rabbit serum to eliminate nonspecific staining. Excess normal serum was removed and replaced by specific primary monoclonal antibody as follows, PMH1 (anti-MUC2) diluted 1:10 and TKH2 (anti-Sialyl-Tn) diluted 1:5 (Kjeldsen, T., Clausen, H., et al. 1988 ). Sections were incubated overnight (18-22 h) at 4°C. After the slides were washed, sections were incubated with biotin-labelled secondary antibody diluted 1:200 in PBS with 5% BSA for 30 min and with ABC for 60 min. Sections were stained for 5 min with 0.05% 3'3 diaminobenzidinetetrahydrochloride (DAB) freshly prepared in 0.05 M tris/hydroxymethylaminomethane (Tris) buffer at pH 7.6, containing 0.01% H 2 O 2 , counterstained with haematoxylin, dehydrated and mounted.
Isotype-specific proximity probes
Secondary proximity ligation probes were prepared by conjugation of isotype-specific anti mouse antibodies to 5'-thiolated oligonucleotides (Soderberg, O., Gullberg, M., et al. 2006) . (Table 2 and Figures 1,2 and 3) , demonstrating close proximity between MUC2 and sialyl-Tn, even when the positivity was focal as in Case 1 (Figure 1 and Table 2 ). In this case, both the IHC for MUC2 and sialyl-Tn and the PLA signals were concentrated in areas with lymphatic permeation (Figure 1, arrows) .
Proximity Ligation Assay for MUC2 and Sialyl-Tn
In localized carcinoma, foci staining only with sialyl-Tn, but not with MUC2 were seen; e.g. (Carneiro, F., Amado, M., et al. 1994 , Carneiro, F., David, L., et al. 1994 , Hanski, C., Hanski, M.L., et al. 1995 , Hoff, S.D., Matsushita, Y., et al. 1989 . In gastric tissues, glycosylation changes, including exposure of simple mucin-type carbohydrate antigens such as Tn, sialyl Tn, and T have been shown in premalignant IM lesions and gastric carcinomas (David, L., Nesland, J.M., et al. 1992) . Similarly, mucin expression patterns have been shown to be modified in these lesions. In IM, there is under-expression/absence of expression of gastric mucins MUC5AC and MUC6, and de novo expression of the intestinal mucin MUC2 (Reis, C.A., David, L., et al. 1999 ). In addition, gastric carcinomas vary in mucin expression pattern; MUC5AC is expressed in 60% of the cases, MUC6 in 30% of the cases, and MUC2 in 25% of the cases (Reis, C.A., David, L., et al. 2000 , Reis, C.A., David, L., et al. 1999 ).
There is circumstantial evidence, mostly based on co-expression profiles, that simple mucintype carbohydrate antigens and mucin genes are coordinately modified in several lesions. In IM, characterized by de novo expression of MUC2 (Reis, C.A., David, L., et al. 1999 ) and sialyl-Tn, it has been shown that both expression profiles overlap in the same cells, namely goblet cells (Ferreira, B., Marcos, N.T., et al. 2006) . This observation raises the possibility that MUC2 serves as the major carrier of sialyl-Tn in IM and gastric carcinomas. We have addressed this issue by using in situ PLA for visualization of glycoproteins in clinical specimens and were able to identify MUC2 as a major carrier of sialyl-Tn.
The importance of these observations lies in the potential that the glycopeptide is more relevant for diagnostic and prognostic evaluation than either the mucin or carbohydrate alone.
In fact, in colorectal cancer it was shown that MUC2-sialyl-Tn co-localization was more frequent in cases with lymph node and distant metastasis, suggesting that MUC2-borne sialylTn might play a role in clinical colorectal cancer metastasis (Wang, F., Goto, M., et al. 2001) .
Despite the limited number of cases in this study, the observation in Case 1 of this publication that MUC2-sialyl-Tn and PLA signals concentrate in cells within lymphatic vessels (Figure 1) suggests that MUC2 carrying sialyl-Tn might facilitate lymphatic metastization.
Our study also clearly demonstrates that co-localization alone is insufficient to determine if the carbohydrate is carried by the mucin with which it co-localizes since we saw discrepancies between IHC co-expression and in situ PLA signals. Future studies will be undertaken to evaluate if other mucins, like MUC5AC and MUC6, can also carry the sialylTn antigen in gastric carcinoma cases. It will also be relevant to evaluate if there is a different biological significance of sialyl-Tn carried by different apomucins or if the observed role played by sialyl-Tn antigen in cancer-cell invasion is independent from the mucin carrier (Pinho et al 2006) . An interesting suggestion raised by the current study is that mucin core proteins and glycosylation changes are co-regulated. Specifically, in IM we know that MUC2 mucin is regulated by CDX2 homeobox gene (Mesquita, P., Jonckheere, N., et al. 2003) and in this study we show that MUC2 is the sialyl-Tn carrier. We therefore hypothesize that CDX2 also regulates expression of ST6GalNAcI, responsible for sialyl-Tn biosyntheis (Marcos, N.T., Pinho, S., et al. 2004) , in line with the regulation already described for β3Gal-T5 involved in other glycan modifications associated with IM (Isshiki, S., Kudo, T., et al. 2003) .
IHC methods using antibodies directed against mucins and cancer associated carbohydrates have been widely used to evaluate the association of both mucins and glycans with clinicopathologic features of the carcinomas. However, limited information has been available regarding the altered O-glycosylation of mucins in cancer lesions. In addition to the co-localization data obtained by multicolour IHC, in situ PLA provides conclusive in situ evidence that a protein is glycosylated with a particular sugar epitope. While mass spectrometry techniques offer hypothesis-free elucidation of the glycosylation of purified proteins, in situ PLA enables localized detection of a hypothesised glycoprotein in clinical samples. In situ PLA signals indicate that the two cancer-associated markers (peptide and carbohydrate moieties) are physically linked and therefore suggest that the peptide has undergone the post translational glycosylation modification. Thus in situ PLA can be used as a method to verify candidate glycoproteins, but will also provide information on expression patterns in tissue making the method applicable for routine diagnostics.
It will also be possible, by utilizing in situ PLA, to extend our current observations and simultaneously determine several different glycan structures in different mucins in order to generate a mucin-glycosylation profile that can provide relevant information for diagnostic and prognostic evaluation. By using proximity ligation sets of three antibodies (Schallmeiner, E., Oksanen, E., et al. 2007 ) it should be possible to identify several glycosylation modifications in an individual mucin molecule.
In summary, by applying the proximity ligation approach to problems in glycobiology, we demonstrated that MUC2 is a major carrier of the cancer-associated sialyl-Tn antigen both in intestinal metaplasia and in gastric carcinomas. Further studies should now explore the relevance of glycopeptide changes as markers in cancer development and progression. 
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